Ritter Pharmaceuticals, Inc. develops therapeutic products, which modulate the human gut microbiome to treat gastrointestinal diseases. The Company is engaged in human gut health research by exploring the metabolic capacity of the gut microbiota. The Company's platform is based on selectively colonizing microbiota (increasing beneficial bacteria) in the colon, and thus changing the colon's composition of microbiota. The Company's first microbiome modulator, RP-G28 is an orally administered galacto-oligosaccharide for the reduction of symptoms associated with lactose intolerance. RP-G28 is used for the growth of lactose-metabolizing bacteria in the colon, such as bifid bacteria and lactobacilli. Its RP-G28 reduces the symptoms and frequency of episodes of abdominal pain, which is associated with lactose intolerance. The primary endpoints included tracking patients' gastrointestinal symptoms through a patient-reported symptom assessment instrument.